ε-sarcoglycan Activators
ε-sarcoglycan Activators encompass a group of chemical compounds that enhance the functional activity of ε-sarcoglycan through various signaling pathways, particularly those mediated by cyclic nucleotides. Forskolin, Isoproterenol, Rolipram, Milrinone, and Dibutyryl-cAMP are all agents that increase intracellular cAMP levels, either by directly activating adenylyl cyclase, binding to beta-adrenergic receptors, or inhibiting phosphodiesterases responsible for cAMP degradation. The elevated cAMP activates protein kinase A (PKA), which can phosphorylate proteins that associate with ε-sarcoglycan, thereby enhancing its stability and function within the sarcoglycan complex, a crucial component in muscle cell integrity and signaling. Similarly, Cilostazol, by inhibiting phosphodiesterase-3, also raises cAMP and supports the same PKA-dependent mechanism, reinforcing ε-sarcoglycan's role in muscle tissues.
cAMP-mediated pathways, several activators operate through the nitric oxide-cGMP axis. L-Arginine serves as a substrate for nitric oxide production, whichthen activates guanylyl cyclase, leading to increased levels of cGMP. This, in turn, activates cGMP-dependent protein kinase (PKG), which can also promote the stabilization and function of ε-sarcoglycan within the dystrophin-glycoprotein complex, essential for muscle cell structure and function. Other compounds like Sildenafil, Sodium Nitroprusside, Zaprinast, and Vardenafil function as phosphodiesterase inhibitors, specifically targeting PDE5, thus preventing the breakdown of cGMP and sustaining its signaling effects. Elevated cGMP levels activate PKG, which may have downstream effects on proteins interacting with ε-sarcoglycan, leading to its enhanced activity. AICAR, by activating AMP-activated protein kinase, taps into a different regulatory mechanism, potentially improving metabolic processes that indirectly stabilize ε-sarcoglycan function. These activators, through their targeted molecular actions, collectively contribute to the upregulation of ε-sarcoglycan activity, thereby enhancing its role in maintaining muscle cell structure and signaling without altering its expression levels.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Forskolin | 66575-29-9 | sc-3562 sc-3562A sc-3562B sc-3562C sc-3562D | 5 mg 50 mg 1 g 2 g 5 g | $78.00 $153.00 $740.00 $1413.00 $2091.00 | 73 | |
This diterpene, derived from Coleus forskohlii, activates adenylyl cyclase, resulting in increased cAMP levels. The boost in cAMP can enhance ε-sarcoglycan activity by cAMP-dependent protein kinase (PKA) activation, which may phosphorylate target proteins that interact with ε-sarcoglycan, stabilizing the sarcoglycan complex and its functions in muscle. | ||||||
Isoproterenol Hydrochloride | 51-30-9 | sc-202188 sc-202188A | 100 mg 500 mg | $28.00 $38.00 | 5 | |
A synthetic catecholamine and beta-adrenergic agonist that can raise intracellular cAMP by stimulating beta-adrenergic receptors, indirectly promoting ε-sarcoglycan's stability through PKA-mediated signaling pathways. | ||||||
Rolipram | 61413-54-5 | sc-3563 sc-3563A | 5 mg 50 mg | $77.00 $216.00 | 18 | |
A selective phosphodiesterase-4 (PDE4) inhibitor, increases intracellular cAMP levels by preventing its breakdown. Elevated cAMP may enhance ε-sarcoglycan function via PKA activation and subsequent phosphorylation of associated proteins. | ||||||
Milrinone | 78415-72-2 | sc-201193 sc-201193A | 10 mg 50 mg | $165.00 $697.00 | 7 | |
A phosphodiesterase-3 inhibitor, increases cAMP concentrations, which can indirectly result in the enhanced activity of ε-sarcoglycan through the PKA pathway, potentially improving its role in muscle maintenance. | ||||||
L-Arginine | 74-79-3 | sc-391657B sc-391657 sc-391657A sc-391657C sc-391657D | 5 g 25 g 100 g 500 g 1 kg | $20.00 $31.00 $61.00 $219.00 $352.00 | 2 | |
A precursor for nitric oxide synthesis, which can activate guanylyl cyclase, increasing cGMP levels. cGMP-dependent protein kinase (PKG) activation may then promote ε-sarcoglycan functional stabilization within the dystrophin-glycoprotein complex. | ||||||
AICAR | 2627-69-2 | sc-200659 sc-200659A sc-200659B | 50 mg 250 mg 1 g | $65.00 $280.00 $400.00 | 48 | |
An activator of AMP-activated protein kinase (AMPK) which can influence metabolic pathways and may indirectly improve the functional stability of ε-sarcoglycan in muscle tissue. | ||||||
Dibutyryl-cAMP | 16980-89-5 | sc-201567 sc-201567A sc-201567B sc-201567C | 20 mg 100 mg 500 mg 10 g | $47.00 $136.00 $492.00 $4552.00 | 74 | |
A cAMP analog resistant to degradation by phosphodiesterases, which can enhance ε-sarcoglycan activity indirectly by stimulating the PKA pathway, potentially affecting the sarcoglycan complex in muscle tissues. | ||||||
Cilostazol | 73963-72-1 | sc-201182 sc-201182A | 10 mg 50 mg | $109.00 $322.00 | 3 | |
A phosphodiesterase-3 inhibitor that can increase cAMP levels, thereby indirectly enhancing ε-sarcoglycan activity through PKA-mediated regulatory effects on muscle cell function. | ||||||
Sodium nitroprusside dihydrate | 13755-38-9 | sc-203395 sc-203395A sc-203395B | 1 g 5 g 100 g | $43.00 $85.00 $158.00 | 7 | |
A donor of nitric oxide that activates guanylyl cyclase, increasing cGMP levels and indirectly enhancing ε-sarcoglycan activity through PKG-mediated signaling pathways. | ||||||
Zaprinast (M&B 22948) | 37762-06-4 | sc-201206 sc-201206A | 25 mg 100 mg | $105.00 $250.00 | 8 | |
A selective phosphodiesterase-5 inhibitor, increases cGMP levels, which could indirectly enhance the activity of ε-sarcoglycan through PKG-dependent signaling, affecting muscle cell function. | ||||||